• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication.

作者信息

Huo Yu-Jia, Xu Peng-Peng, Fu Di, Yi Hong-Mei, Huang Yao-Hui, Wang Li, Wang Nan, Ji Meng-Meng, Liu Qing-Xiao, Shi Qing, Wang Shuo, Cheng Shu, Feng Yan, Zhao Wei-Li

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Blood Cancer J. 2022 Mar 29;12(3):48. doi: 10.1038/s41408-022-00644-2.

DOI:10.1038/s41408-022-00644-2
PMID:35351868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8964673/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/8964673/fab84cd6d93d/41408_2022_644_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/8964673/c09b51b5f854/41408_2022_644_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/8964673/fab84cd6d93d/41408_2022_644_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/8964673/c09b51b5f854/41408_2022_644_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/8964673/fab84cd6d93d/41408_2022_644_Fig2_HTML.jpg

相似文献

1
Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication.具有预后意义和治疗意义的CD30+弥漫性大B细胞淋巴瘤的分子异质性
Blood Cancer J. 2022 Mar 29;12(3):48. doi: 10.1038/s41408-022-00644-2.
2
Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.CD30 表达对弥漫性大 B 细胞淋巴瘤预后意义的系统评价：荟萃分析。
J Oral Pathol Med. 2021 Jul;50(6):587-593. doi: 10.1111/jop.13208. Epub 2021 Jun 28.
3
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.CD30 表达定义了一种具有良好预后和独特基因表达特征的弥漫性大 B 细胞淋巴瘤新型亚组：来自国际弥漫性大 B 细胞淋巴瘤利妥昔单抗-CHOP 联合方案研究的报告。
Blood. 2013 Apr 4;121(14):2715-24. doi: 10.1182/blood-2012-10-461848. Epub 2013 Jan 23.
4
CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.R-EPOCH方案治疗的弥漫性大B细胞淋巴瘤患者中CD30的表达及预后意义
Hum Pathol. 2017 Feb;60:160-166. doi: 10.1016/j.humpath.2016.10.009. Epub 2016 Nov 2.
5
CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.CD30 表达及其与 MYC 和 BCL2 在初发性弥漫性大 B 细胞淋巴瘤中的相关性。
J Clin Pathol. 2018 Sep;71(9):795-801. doi: 10.1136/jclinpath-2018-205039. Epub 2018 Apr 17.
6
[Expression of CD30 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].[CD30在弥漫性大B细胞淋巴瘤中的表达及其临床意义]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Jun;24(3):717-21. doi: 10.7534/j.issn.1009-2137.2016.03.015.
7
CD30, another useful predictor of survival in DLBCL?CD30是弥漫性大B细胞淋巴瘤（DLBCL）中另一个有用的生存预测指标？
Blood. 2013 Apr 4;121(14):2582-3. doi: 10.1182/blood-2013-02-481978.
8
A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15?
Leuk Lymphoma. 2010 Jun;51(6):1148-51. doi: 10.3109/10428194.2010.480820.
9
Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.中国患者中CD30阳性原发性弥漫性大B细胞淋巴瘤的患病率及临床病理特征：一项232例病例的回顾性研究
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15825-35. eCollection 2015.
10
[Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].[弥漫性大B细胞淋巴瘤患者CD30的表达及临床意义]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):450-457. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.020.

引用本文的文献

1
Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.早期化疗免疫治疗失败的弥漫性大B细胞淋巴瘤的特征及预测模型
Front Immunol. 2025 Jun 16;16:1553850. doi: 10.3389/fimmu.2025.1553850. eCollection 2025.
2
Molecular heterogeneity of CD30 peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study.具有预后意义和治疗意义的CD30外周T细胞淋巴瘤的分子异质性：一项回顾性多中心研究
EBioMedicine. 2025 May;115:105693. doi: 10.1016/j.ebiom.2025.105693. Epub 2025 Apr 10.
3
Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism.

本文引用的文献

1
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.用于治疗淋巴瘤的抗体药物偶联物：临床进展与最新成果
J Hematol Oncol. 2021 Jun 5;14(1):88. doi: 10.1186/s13045-021-01097-z.
2
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.CREBBP/EP300 突变通过 FBXW7-NOTCH-CCL2/CSF1 轴改变肿瘤相关巨噬细胞极化促进弥漫性大 B 细胞淋巴瘤的肿瘤进展。
Signal Transduct Target Ther. 2021 Jan 11;6(1):10. doi: 10.1038/s41392-020-00437-8.
3
T follicular helper cells in germinal center B cell selection and lymphomagenesis.
靶向T细胞淋巴瘤中CD30的抗体药物偶联物：临床进展与机制
Cancers (Basel). 2025 Feb 2;17(3):496. doi: 10.3390/cancers17030496.
4
Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.64Cu/177Lu标记的抗CD30单克隆抗体用于CD30阳性淋巴瘤诊疗的临床前评估
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1751-1763. doi: 10.1007/s00259-024-07022-z. Epub 2024 Dec 17.
5
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.肿瘤生物学隐藏了弥漫性大 B 细胞淋巴瘤的新治疗方法：叙述性综述。
Int J Mol Sci. 2024 Oct 23;25(21):11384. doi: 10.3390/ijms252111384.
6
Specific mortality in patients with diffuse large B-cell lymphoma: a retrospective analysis based on the surveillance, epidemiology, and end results database.弥漫性大 B 细胞淋巴瘤患者的特定死亡率：基于监测、流行病学和最终结果数据库的回顾性分析。
Eur J Med Res. 2024 Apr 20;29(1):241. doi: 10.1186/s40001-024-01833-4.
7
Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.淋巴瘤中CD30分子的作用机制及治疗靶点
Front Oncol. 2023 Dec 22;13:1301437. doi: 10.3389/fonc.2023.1301437. eCollection 2023.
8
Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中国际预后指数的生物学特征。
Blood Adv. 2024 Apr 9;8(7):1587-1599. doi: 10.1182/bloodadvances.2023011425.
9
[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].[用维布妥昔单抗治疗CD30阳性淋巴瘤的进展]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):81-86. doi: 10.3760/cma.j.issn.0253-2727.2023.01.018.
10
CD58 loss in tumor cells confers functional impairment of CAR T cells.肿瘤细胞中 CD58 的缺失导致 CAR T 细胞功能受损。
Blood Adv. 2022 Nov 22;6(22):5844-5856. doi: 10.1182/bloodadvances.2022007891.
生发中心 B 细胞选择和淋巴瘤发生中的 T 滤泡辅助细胞。
Immunol Rev. 2020 Jul;296(1):48-61. doi: 10.1111/imr.12860. Epub 2020 May 15.
4
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.原发性纵隔 B 细胞淋巴瘤的生物学和治疗：现状与未来方向。
Br J Haematol. 2019 Apr;185(1):25-41. doi: 10.1111/bjh.15778. Epub 2019 Feb 10.
5
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.靶向癌症中的 B 细胞受体信号：临床前和临床进展。
Nat Rev Cancer. 2018 Mar;18(3):148-167. doi: 10.1038/nrc.2017.121. Epub 2018 Jan 19.
6
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.调节PD-L1和PD-L2表达的干扰素受体信号通路
Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.
7
The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.CREBBP 乙酰转移酶是 B 细胞淋巴瘤中的单倍剂量不足肿瘤抑制因子。
Cancer Discov. 2017 Mar;7(3):322-337. doi: 10.1158/2159-8290.CD-16-1417. Epub 2017 Jan 9.
8
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.大规模基因芯片分析揭示非霍奇金淋巴瘤免疫逃逸的四个阶段。
Oncoimmunology. 2016 May 19;5(7):e1188246. doi: 10.1080/2162402X.2016.1188246. eCollection 2016 Jul.
9
NF-κB: Regulation by Methylation.核因子κB：甲基化调控
Cancer Res. 2015 Sep 15;75(18):3692-5. doi: 10.1158/0008-5472.CAN-15-1022. Epub 2015 Sep 3.
10
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.致癌转录因子IRF4在外周T细胞淋巴瘤中受新型CD30/NF-κB正反馈环调控。
Blood. 2015 May 14;125(20):3118-27. doi: 10.1182/blood-2014-05-578575. Epub 2015 Apr 1.